Leadership Team
Jose Saro, Chief Medical Officer
Jose has over 25 years of experience in the preclinical, translational and clinical development of oncology compounds. Throughout his career, he has developed an extensive global network among oncologic academic institutions and the pharmaceutical industry.
Jose joined Light Chain Bioscience – NovImmune SA as CMO in May 2023, his previous position was at Adaptimmune Therapeutics, as Vice-President global Medical Development, leading the clinical development of Adaptimmune’s cell therapy pipeline.
Previously, he led the ceralasertib post-PARP inhibitor early clinical development program in solid tumors at AstraZeneca. Prior to that, he worked at Avacta as Chief Medical Officer driving the development strategy of Affimer® programs into the clinic. Before Avacta, Dr. Saro served as Senior Translational Medicine Leader at Roche where he ran three global immunotherapy programs – a targeted cytokine, and two T-cell bispecific antibodies in solid tumors – in collaboration with top academic institutions in the EU and US. Previously, he led global clinical programs at Bristol Myers Squibb including dasatinib, ipilimumab (anti-CTLA4), nivolumab (anti-PD1), anti-PDL1, anti-KIR, anti-LAG3, brivanib, a MEK inhibitor, and elotuzumab. While at Novartis he focused on biomarkers in the preclinical and clinical settings. Dr. Saro earned a medical degree from the University of Oviedo, Spain and a master’s degree in pharmaceutical medicine from Complutense University of Madrid, Spain.
